Detalles de la búsqueda
1.
Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database.
Mod Rheumatol
; 34(2): 287-296, 2024 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37039670
2.
Subjective symptoms contributing to the quality of life of rheumatoid arthritis patients with clinical remission from the IORRA database.
Mod Rheumatol
; 33(3): 496-502, 2023 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35652691
3.
Nationwide clinical and epidemiological study of large-vessel vasculitis in Japan in 2017.
Mod Rheumatol
; 34(1): 167-174, 2023 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36737863
4.
Association between patient-reported outcomes and impairments in work and activity in patients with rheumatoid arthritis in clinical remission: A retrospective analysis using the IORRA database.
Mod Rheumatol
; 33(5): 899-905, 2023 Aug 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36094815
5.
Geographic variations in rheumatoid arthritis treatment in Japan: A nationwide retrospective study using the national database of health insurance claims and specific health checkups of Japan.
Mod Rheumatol
; 32(1): 105-113, 2022 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33818268
6.
Trends in actual medication use for child-onset systemic lupus erythematosus using the Japanese health insurance database 2009-18.
Mod Rheumatol
; 32(3): 565-570, 2022 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34908147
7.
Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: Results from a Japanese multi-institutional retrospective study.
Mod Rheumatol
; 32(1): 16-23, 2022 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33428479
8.
Differences in patients' population and efficacy/effectiveness of biologic disease-modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis - using the IORRA cohort.
Mod Rheumatol
; 32(4): 675-685, 2022 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34918127
9.
The risk of hospitalized infection in patients with systemic lupus erythematosus treated with hydroxychloroquine.
Lupus
; 29(13): 1712-1718, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32838624
10.
Higher risk of hospitalized infection, cardiovascular disease, and fracture in patients with rheumatoid arthritis determined using the Japanese health insurance database.
Mod Rheumatol
; 29(5): 788-794, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30484352
11.
Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan.
Mod Rheumatol
; 27(5): 787-794, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27846756
12.
Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy.
Mod Rheumatol
; 27(5): 811-819, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27919205
13.
Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.
Mod Rheumatol
; 26(5): 642-50, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26873430
14.
High prevalence of cardiovascular comorbidities in patients with rheumatoid arthritis from a population-based cross-sectional study of a Japanese health insurance database.
Mod Rheumatol
; 26(4): 522-8, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26666766
15.
Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia.
Mod Rheumatol
; 25(4): 609-14, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25496409
16.
The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database.
Rheumatol Int
; 34(12): 1729-36, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24852650
17.
A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan.
Mod Rheumatol
; 24(4): 572-9, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24320747
18.
Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database.
RMD Open
; 10(2)2024 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38886005
19.
Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients.
Mod Rheumatol
; 23(6): 1085-93, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23212592
20.
Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
Ann Rheum Dis
; 71(11): 1820-6, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22504558